{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:47:42Z","timestamp":1761896862612,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T00:00:00Z","timestamp":1533859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T00:00:00Z","timestamp":1533859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s13300-018-0478-1","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T15:43:05Z","timestamp":1533915785000},"page":"1919-1930","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting"],"prefix":"10.1007","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0671-0778","authenticated-orcid":false,"given":"Marc","family":"Evans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roopa","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Gundgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barrie","family":"Chubb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,10]]},"reference":[{"issue":"Suppl. 2","key":"478_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1463-1326.2008.00845.x","volume":"10","author":"P Levin","year":"2008","unstructured":"Levin P. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics. Diabetes Obes Metab. 2008;10(Suppl. 2):66\u201375.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"478_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.2017.7115","volume":"318","author":"Wendy Lane","year":"2017","unstructured":"Lane W, Bailey TS, Gerety G, Gumprecht J, Philis-Tsimikas A, Hansen CT, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. JAMA. 2017;318:33\u201344.","journal-title":"JAMA"},{"issue":"1","key":"478_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jama.2017.7117","volume":"318","author":"Carol Wysham","year":"2017","unstructured":"Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA. 2017;318:45\u201356.","journal-title":"JAMA"},{"key":"478_CR4","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/j.1463-1326.2012.01638.x","volume":"14","author":"T Heise","year":"2012","unstructured":"Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14:944\u201350.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"478_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/1753-0407.12266","volume":"8","author":"Tim Heise","year":"2015","unstructured":"Heise T, Korsatko S, Nosek L, Coester HV, Deller S, Roepstorff C, et al. Steady state is reached within 2\u20133\u00a0days of once-daily administration of degludec, a basal insulin with an ultralong duration of action. J Diabetes. 2016;8:132\u20138.","journal-title":"Journal of Diabetes"},{"key":"478_CR6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1463-1326.2012.01627.x","volume":"14","author":"T Heise","year":"2012","unstructured":"Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14:859\u201364.","journal-title":"Diabetes Obes Metab"},{"key":"478_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/dom.12032","volume":"15","author":"R Ratner","year":"2013","unstructured":"Ratner R, Gough SC, Mathieu C, Del Prato S, Bode B, Mersebach H, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15:175\u201384.","journal-title":"Diabetes Obes Metab"},{"key":"478_CR8","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1111\/j.1464-5491.2012.03657.x","volume":"29","author":"AJ Farmer","year":"2012","unstructured":"Farmer AJ, Brockbank KJ, Keech ML, England EJ, Deakin CD. Incidence and costs of severe hypoglycaemia requiring attendance by the emergency medical services in South Central England. Diabet Med. 2012;29:1447\u201350.","journal-title":"Diabet Med"},{"key":"478_CR9","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2147\/PPA.S46805","volume":"7","author":"SB Harris","year":"2013","unstructured":"Harris SB, Khunti K, Landin-Olsson M, Galbo-J\u00f8rgensen CB, B\u00f8gelund M, Chubb B, et al. Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective. Patient Prefer Adherence. 2013;7:925\u201336.","journal-title":"Patient Prefer Adherence"},{"key":"478_CR10","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/dme.12844","volume":"33","author":"SR Heller","year":"2016","unstructured":"Heller SR, Frier BM, Hersl\u00f8v ML, Gundgaard J, Gough SC. Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources. Diabet Med. 2016;33:471\u20137.","journal-title":"Diabet Med"},{"key":"478_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1586\/erp.12.80","volume":"13","author":"WD Willis","year":"2013","unstructured":"Willis WD, Diago-Cabezudo JI, Madec-Hily A, Aslam A. Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: results from a European online survey. Expert Rev Pharmacoecon Outcomes Res. 2013;13:123\u201330.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"478_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3111\/13696998.2014.971160","volume":"18","author":"M Evans","year":"2015","unstructured":"Evans M, Wolden M, Gundgaard J, Chubb B, Christensen T. Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK. J Med Econ. 2015;18:56\u201368.","journal-title":"J Med Econ"},{"key":"478_CR13","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.2337\/dc12-2480","volume":"36","author":"ER Seaquist","year":"2013","unstructured":"Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycaemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384\u201395.","journal-title":"Diabetes Care"},{"unstructured":"Haymarket Media Group. MIMS (Monthly Index of Medical Specialties). Available at www.mims.co.uk. Last accessed 28 June 2018.","key":"478_CR14"},{"key":"478_CR15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3111\/13696990903336597","volume":"12","author":"M Hammer","year":"2009","unstructured":"Hammer M, Lammert M, Mej\u00edas SM, Kern W, Frier BM. Costs of managing severe hypoglycaemia in three European countries. J Med Econ. 2009;12:281\u201390.","journal-title":"J Med Econ"},{"unstructured":"HCHS: The Hospital & Community Health Services (HCHS) index. Available at https:\/\/kar.kent.ac.uk\/65559\/40\/65559_rep_UCR-2017-v13finalKAR.pdf. Last accessed 16 April 2018.","key":"478_CR16"},{"issue":"7","key":"478_CR17","doi-asserted-by":"publisher","first-page":"A611","DOI":"10.1016\/j.jval.2015.09.2118","volume":"18","author":"B Chubb","year":"2015","unstructured":"Chubb B, Tikkanen C. The cost of non-severe hypoglycaemia in Europe. Value Health. 2015;18:A611.","journal-title":"Value in Health"},{"key":"478_CR18","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1477-7525-11-90","volume":"11","author":"M Evans","year":"2013","unstructured":"Evans M, Khunti K, Mamdani M, Galbo-J\u00f8rgensen CB, Gundgaard J, B\u00f8gelund M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes. 2013;11:90.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"478_CR19","doi-asserted-by":"publisher","first-page":"21240","DOI":"10.3402\/jmahp.v1i0.21240","volume":"1","author":"Erpur Adalsteinsson","year":"2013","unstructured":"Adalsteinsson E, Toumi M. Benefits of probabilistic sensitivity analysis\u2014a review of NICE decisions. J Mark Access Health Policy. 2013;1. https:\/\/doi.org\/10.3402\/jmahp.v1i0.21240.","journal-title":"Journal of Market Access & Health Policy"},{"issue":"1","key":"478_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s13300-016-0157-z","volume":"7","author":"Lisa Elliott","year":"2016","unstructured":"Elliott L, Fidler C, Ditchfield A, Stissing T. Hypoglycemia event rates: a comparison between real-world data and randomized controlled trial populations in insulin-treated diabetes. Diabetes Ther. 2016;7:45\u201360.","journal-title":"Diabetes Therapy"},{"key":"478_CR21","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/dom.12250","volume":"16","author":"M Evans","year":"2014","unstructured":"Evans M, Wolden M, Gundgaard J, Chubb B, Christensen T. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin\u2014from the UK health care cost perspective. Diabetes Obes Metab. 2014;16:366\u201375.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"478_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s13300-017-0236-9","volume":"8","author":"Marc Evans","year":"2017","unstructured":"Evans M, Chubb B, Gundgaard J. Cost-effectiveness of insulin degludec versus insulin glargine in adults with type 1 and type 2 diabetes mellitus. Diabetes Ther. 2017;8:275\u201391.","journal-title":"Diabetes Therapy"},{"issue":"2","key":"478_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3111\/13696998.2014.975234","volume":"18","author":"Marc Evans","year":"2014","unstructured":"Evans M, McEwan P, Foos V. Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice\u2014a case-based evaluation. J Med Econ. 2015;18:96\u2013105.","journal-title":"Journal of Medical Economics"},{"key":"478_CR24","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1080\/03007995.2016.1277194","volume":"33","author":"L Landstedt-Hallin","year":"2017","unstructured":"Landstedt-Hallin L, Gundgaard J, Ericsson \u00c5, Ellfors-Zetterlund S. Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data. Curr Med Res Opin. 2017;33:647\u201355.","journal-title":"Curr Med Res Opin"},{"key":"478_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2165\/00019053-199609020-00003","volume":"9","author":"G Karlsson","year":"1996","unstructured":"Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. Pharmacoeconomics. 1996;9:113\u201320.","journal-title":"Pharmacoeconomics"},{"key":"478_CR26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1463-1326.2008.00976.x","volume":"11","author":"M Monami","year":"2009","unstructured":"Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab. 2009;11:372\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"478_CR27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/dme.13317","volume":"34","author":"P. L. Kristensen","year":"2017","unstructured":"Kristensen PL, Tarnow L, Bay C, N\u00f8rgaard K, Jensen T, Parving HH, et al. Comparing effects of insulin analogues and human insulin on nocturnal glycaemia in hypoglycaemia-prone people with type 1 diabetes. Diabet Med. 2017;34:625\u201331.","journal-title":"Diabetic Medicine"},{"key":"478_CR28","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.diabres.2008.04.007","volume":"81","author":"M Monami","year":"2008","unstructured":"Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008;81:184\u20139.","journal-title":"Diabetes Res Clin Pract"},{"key":"478_CR29","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1586\/erp.11.73","volume":"11","author":"DC Suh","year":"2011","unstructured":"Suh DC, Aagren M. Cost-effectiveness of insulin detemir: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2011;11:641\u201355.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"478_CR30","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1185\/030079904X5661","volume":"20","author":"AJ Palmer","year":"2004","unstructured":"Palmer AJ, Roze S, Valentine WJ, Smith I, Wittrup-Jensen KU. Cost-effectiveness of detemir-based basal\/bolus therapy versus NPH-based basal\/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials. Curr Med Res Opin. 2004;20:1729\u201346.","journal-title":"Curr Med Res Opin"},{"key":"478_CR31","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1185\/030079907X182194","volume":"23","author":"AJ Palmer","year":"2007","unstructured":"Palmer AJ, Valentine WJ, Ray JA, Foos V, Lurati F, Smith I, et al. An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK. Curr Med Res Opin. 2007;23:895\u2013901.","journal-title":"Curr Med Res Opin"},{"key":"478_CR32","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.2337\/dc10-1915","volume":"34","author":"SS Johnston","year":"2011","unstructured":"Johnston SS, Conner C, Aagren M, Smith DM, Bouchard J, Brett J. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care. 2011;34:1164\u201370.","journal-title":"Diabetes Care"},{"issue":"2","key":"478_CR33","doi-asserted-by":"publisher","first-page":"316","DOI":"10.2337\/dc14-0920","volume":"38","author":"K Khunti","year":"2015","unstructured":"Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care. 2015;38(2):316\u201322.","journal-title":"Diabetes Care"},{"key":"478_CR34","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.2337\/dc14-0405","volume":"37","author":"TW Lung","year":"2014","unstructured":"Lung TW, Petrie D, Herman WH, Palmer AJ, Svensson AM, Eliasson B, Clarke PM. Severe hypoglycemia and mortality after cardiovascular events for type 1 diabetic patients in Sweden. Diabetes Care. 2014;37:2974\u201381.","journal-title":"Diabetes Care"},{"issue":"Suppl. 5","key":"478_CR35","doi-asserted-by":"publisher","first-page":"S155","DOI":"10.1016\/j.jcjd.2015.09.009","volume":"39","author":"B Paty","year":"2015","unstructured":"Paty B. The role of hypoglycemia in cardiovascular outcomes in diabetes. Can J Diabetes. 2015;39(Suppl. 5):S155\u20139.","journal-title":"Can J Diabetes"},{"issue":"Suppl. 1","key":"478_CR36","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1089\/dia.2012.0031","volume":"14","author":"JK Snell-Bergeon","year":"2012","unstructured":"Snell-Bergeon JK, Wadwa RP. Hypoglycemia, diabetes, and cardiovascular disease. Diabetes Technol Ther. 2012;14(Suppl. 1):S51\u20138.","journal-title":"Diabetes Technol Ther"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-018-0478-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-018-0478-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-018-0478-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:19:48Z","timestamp":1724411988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-018-0478-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,10]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["478"],"URL":"https:\/\/doi.org\/10.1007\/s13300-018-0478-1","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"type":"print","value":"1869-6953"},{"type":"electronic","value":"1869-6961"}],"subject":[],"published":{"date-parts":[[2018,8,10]]},"assertion":[{"value":"20 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}